RNA vs V · rev $22.6M vs P/E 33, rev $40.00B
Atrium Therapeutics, Inc. Common Stock (RNA) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
RNA currently screens at market cap $217.5M. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the RNA and V stock pages for the full models.
Not investment advice.